Regeneron Pharmaceuticals (REGN) Rallies On Earnings Beat As Undervalued Narrative Holds

Regeneron Pharmaceuticals (REGN) shares have been in focus after the company reported quarterly revenue of US$4.29b, up 16.7% year on year. The results beat analyst expectations and have lifted the stock about 12.4% since the release. Regeneron Pharmaceuticals has been in a strong upswing, with a 7-day share price return of 7.68% and a 90-day share price return of 17.68%. The 1-year total shareholder return of 40.63% reflects momentum that has built over time as new drug data, expanded...